Key result
ICD remains first-line therapy to mitigate malignant arrhythmic risk in short QT syndrome.
Why the study?
Short QT syndrome is a rare inherited cardiac channelopathy with malignant natural history requiring summarization of current diagnostic and treatment data.
This review provides a comprehensive overview of Short QT Syndrome, emphasizing its genetic basis, diagnostic criteria, and the critical role of ICDs as first-line therapy.
ICDs remain first-line for short QT syndrome; review leaves open gaps in risk stratification and alternative therapies.
Short QT syndrome (SQTS) is an inherited cardiac channelopathy characterised by an abnormally short QT interval and increased risk for atrial and ventricular arrhythmias. Diagnosis is based on the evaluation of symptoms (syncope or cardiac arrest), family history and electrocardiogram (ECG) findings. Mutations of cardiac ion channels responsible for the repolarisation orchestrate electrical heterogeneity during the action potential and provide substrate for triggering and maintaining of tachyarrhythmias. Due to the malignant natural history of SQTS, implantable cardioverter defibrillator (ICD) is the first-line therapy in affected patients. This review summarises current data and addresses the genetic basis and clinical features of SQTS.
No takes yet. Share an insight, caveat, or question.
Rudic et al. (2014) conducted a review in Short QT Syndrome. Short QT syndrome is an inherited cardiac channelopathy with a malignant natural history, for which an implantable cardioverter defibrillator is considered the first-line therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: